CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
SAGITTARIUS focuses on improving treatment for patients with high-risk colon cancer by using a blood test to detect residual disease after surgery. This personalized approach aims to tailor chemotherapy based on individual risk, enhancing treatment effectiveness and reducing unnecessary side effects.
SAGITTARIUS aim to optimize the clinical management of locoregional stage II high-risk/stage III colon cancer (LRCC).
Approximately half of all LRCC patients relapse within two years from time of curative surgery because of imaging-undetectable micro-metastatic residual disease (MMRD).
Given the lack of reliable predictors of individual risk, LRCC patients are treated with a one-fits-all adjuvant chemotherapy.
This gunshot approach results in either over- or under-treatment.
Measuring circulatin…
IFOM-ISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, MILAN
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Spain, Barcelona
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Milano
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
